Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines

PURPOSE: The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi-Ae, Choi, Jeong-Hee, Shin, Yoo-Seob, Park, Hae-Sim, Ye, Young-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359646/
https://www.ncbi.nlm.nih.gov/pubmed/37153977
http://dx.doi.org/10.4168/aair.2023.15.4.496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359646/
https://www.ncbi.nlm.nih.gov/pubmed/37153977
http://dx.doi.org/10.4168/aair.2023.15.4.496

Ejemplares similares